Fatty Liver News and Research

Latest Fatty Liver News and Research

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

Imbalance between neutrophil elastase and α1-antitrypsin leads to obesity, inflammation

Many recent studies have suggested that obesity is associated with chronic inflammation in fat tissues. Researchers at Sanford-Burnham Medical Research Institute have discovered that an imbalance between an enzyme called neutrophil elastase and its inhibitor causes inflammation, obesity, insulin resistance, and fatty liver disease.

3 Apr 2013

Drugs that combat ageing may be available within five years

Drugs that combat ageing may be available within five years, following landmark work led by an Australian researcher.

11 Mar 2013

Deleting Plin2 gene prevents obesity in mice

Researchers have discovered that deleting a specific gene in mice prevents them from becoming obese even on a high fat diet, a finding they believe may be replicated in humans.

6 Mar 2013

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Florida Hospital announced today that they have renewed a research agreement with Takeda Pharmaceutical Company Limited (Takeda) to extend their collaboration to discover and evaluate new therapeutic approaches to obesity. The collaboration uses a research and drug-development model that creates an early feedback loop in the discovery pipeline.

12 Feb 2013

MRI promising for noninvasive hepatic steatosis assessment

Magnetic resonance imaging allows accurate measurement of the extent and severity of hepatic steatosis in patients with nonalcoholic fatty liver disease, demonstrate the results of two studies published in Radiology.

11 Feb 2013

Amlexanox also reverses obesity, diabetes and fatty liver in mice

Researchers at the University of Michigan's Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.

11 Feb 2013

Donor liver quality: an interview with Dr Eric Orman

Liver transplantation is a surgical procedure in which a liver (or part of a liver) is removed from a donor and placed into a recipient. Although some transplants use a portion of the liver of living donors, the vast majority of donors are deceased.

6 Feb 2013

DHA more effective than EPA in preventing liver inflammation and fibrosis

Research at Oregon State University has found that one particular omega-3 fatty acid has a powerful effect in preventing liver inflammation and fibrosis - common problems that are steadily rising along with the number of Americans who are overweight.

6 Feb 2013

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

1 Feb 2013

TSC22D4 gene plays a key role in the onset of cachexia

Cachexia or wasting is a condition affecting up to 70 percent of cancer patients, depending on the type of cancer. It is characterized by a dramatic loss of body weight that is independent of food intake. Cachexia is seen particularly often and most pronounced in patients suffering from cancers of the digestive tract and the lungs.

16 Jan 2013

SR9238 compound can reverse effects of fatty liver disease

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed the first synthetic compound that can reverse the effects of a serious metabolic condition known as fatty liver disease. True to its name, the disease involves an abnormal buildup of fat in the liver.

20 Dec 2012

LSUHSC to advance research on social, genetic, environmental and behavioral determinants of future obesity

Melinda Sothern, PhD, CEP, Professor and Director of the Behavioral and Community Health Sciences Program at LSU Health Sciences Center New Orleans School of Public Health, has been awarded $675,000 in grant funding to advance her research on the role of social, genetic, environmental and behavioral determinants of future obesity.

7 Dec 2012

Researchers unlock mechanisms of how the body converts dietary carbohydrates into fat

A gene that helps the body convert that big plate of holiday cookies you just polished off into fat could provide a new target for potential treatments for fatty liver disease, diabetes and obesity.

6 Dec 2012

Link between high fructose corn syrup intake and diabetes prevalence

A new study by University of Southern California (USC) and University of Oxford researchers indicates that large amounts of high fructose corn syrup (HFCS) found in national food supplies across the world may be one explanation for the rising global epidemic of type 2 diabetes and resulting higher health care costs.

28 Nov 2012

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".

26 Nov 2012

Dietary habits associated with NAFLD in obese children

Research has identified a number of variables associated with nonalcoholic fatty liver disease in obese children.

27 Sep 2012

MiR-34a plays a key role in obesity

Scientists have identified a key molecular player in a chain of events in the body that can lead to fatty liver disease, Type II diabetes and other metabolic abnormalities associated with obesity. By blocking this molecule, the researchers were able to reverse some of the pathology it caused in obese mice.

21 Sep 2012

Hyperuricemia associated with more severe hepatic ATP depletion in response to fructose intake

Obese patients with type 2 diabetes who consume higher amounts of fructose display reduced levels of liver adenosine triphosphate (ATP)—a compound involved in the energy transfer between cells.

14 Sep 2012